Longevity · Cellular energy
NAD+ IV therapy: what the science actually supports
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme essential to mitochondrial energy production. It declines steeply with age — postmenopausal women often have 40–60% less NAD+ than they did in their 20s. IV therapy is the most direct way to raise circulating levels, but oral precursors and injections are more practical for daily use.
Why NAD+ declines with age
NAD+ is consumed by three enzyme families: sirtuins (longevity), PARPs (DNA repair), and CD38 (immune signaling). CD38 activity rises with age, accelerating NAD+ depletion. Estrogen loss further increases oxidative stress, which increases PARP demand for NAD+.
What IV NAD+ actually does
- Rapidly raises circulating NAD+ (measurable within hours)
- Bypasses first-pass metabolism
- Reported: improved mental clarity, energy, and hangover-like fatigue reduction
The evidence, honestly
Direct RCTs of IV NAD+ in humans are limited to small trials (n<30) in Parkinson's disease and addiction recovery. Most claims come from patient-reported outcomes and mechanistic biology. Oral NR and NMN have stronger controlled-trial data for raising tissue NAD+.
Alternatives
Subcutaneous NAD+ injections (self-administered at home) deliver a similar biochemical outcome at a fraction of the cost. Oral NMN and NR are the most evidence-supported daily strategies.
Frequently asked questions
How much does NAD+ IV therapy cost?
Typically $300–$800 per infusion. A loading protocol is usually 4–6 infusions over 2 weeks, then monthly maintenance.
How long does an NAD+ IV take?
2–4 hours. Infusion speed is limited by side effects — pushing too fast causes chest tightness, nausea, and flushing.
NAD+ IV vs oral NMN/NR?
IV raises blood NAD+ 10x higher than oral precursors, but oral NMN and NR raise <em>tissue</em> NAD+ steadily over weeks and are far more practical for daily use.
What does NAD+ do in menopause?
Supports mitochondrial energy, DNA repair (via sirtuins and PARPs), and neurotransmitter synthesis — all of which decline in perimenopause and menopause.
Is NAD+ IV therapy FDA-approved?
No. NAD+ IV is not FDA-approved for any specific indication. It is administered off-label at IV clinics and longevity practices.
Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.
Request your Longevity Consult →Explore Kindr Health
Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service
Written and medically reviewed by the Kindr Health Clinical Team · Published 2026-06-19 · Last reviewed 2026-07-01. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.